<PAGE> 1
- ------------------------------------------------------------------------------
- ------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under
Section 12(g) of the Securities Exchange Act of 1934 or
Suspension of Duty to File Reports
Under Sections 13 and 15(d) of the Securities
Exchange Act of 1934.
Commission File Number 0-20963
UROQUEST MEDICAL CORPORATION
(Exact Name of Registrant as Specified in its Charter)
265 East 100 South, Suite 220
Salt Lake City, Utah 84111
(801) 322-1554
(Address, including zip code, and telephone number,
including area code, of registrant's
principal executive offices)
Common Stock
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for
which a duty to file reports under
section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) /X/ Rule 12h-3(b)(1)(ii) / /
Rule 12g-4(a)(1)(ii) /X/
Rule 12g-4(a)(2)(i) / / Rule 12h-3(b)(2)(i) / /
Rule 12g-4(a)(2)(ii) / / Rule 12h-3(b)(2)(ii) / /
Rule 12h-3(b)(1)(i) / / Rule 15d-6 / /
Approximate number of holders of record as of the certification or
notice date: 75
Pursuant to the requirements of the Securities Exchange Act of 1934,
UroQuest Medical Corporation has caused this certification/notice to be signed
on its behalf by the undersigned duly authorized person.
DATE: October 11, 1996. BY: /s/ Gregory S. Ayers
--------------------------------
Gregory S. Ayers, Vice President and
Chief Financial Officer
- ------------------------------------------------------------------------------
